XBI is trading 3% down at $151.50 as biotech stocks slide alongside a sharper tech and AI-led sell-off.
- Investors are trimming exposure to higher-risk growth sectors amid geopolitical tensions, rate uncertainty, and market-wide volatility.
- The move is driven by broader macro sentiment rather than ETF-specific catalysts, earnings, or regulatory events.